5 citations
,
January 2022 in “Dermatology Reports” Tofacitinib treatment for hair loss may worsen acne.
4 citations
,
June 2013 in “The Journal of Rheumatology” The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.
May 2012 in “Journal of Clinical Oncology” Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.
14 citations
,
May 2008 in “Journal of proteome research” Dutasteride may help reduce brain plaque linked to Alzheimer's by affecting cell energy structures and waste removal.
October 2022 in “International Research Journal of Modernization in Engineering Technology and Science” COVID-19 vaccines may cause hair loss in people who are genetically prone to it.
24 citations
,
January 2018 in “International Journal of Trichology” Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
AnnoPharma effectively identifies substances causing adverse drug reactions in medical abstracts.
16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
44 citations
,
October 2009 in “Journal of the American Academy of Dermatology” Topical bexarotene 1% gel might help regrow hair in alopecia areata and is generally safe.
2 citations
,
June 2020 in “Clinical & experimental allergy/Clinical and experimental allergy” Referral rates for anaphylaxis patients improved significantly after implementing guidelines.
November 2007 in “Hospital pharmacy” The conclusion is that healthcare professionals should report adverse drug reactions to improve medication safety and patient care.
3 citations
,
February 2016 in “Nature Biotechnology” New drug shows promise for better hair growth in baldness treatment.
November 2022 in “Orphanet Journal of Rare Diseases” Long-term use of androgens can help manage Hereditary Angioedema (HAE) but may cause serious side effects, so alternative treatments with fewer side effects are being considered.
2 citations
,
March 2013 in “Phytotherapy Research” Ascorbigen increases hair cell growth in a lab setting but does not prevent hair loss from chemotherapy in mice.
July 2025 in “Jurnal Farmasi Sains dan Praktis” Most adverse reactions to the treatment were mild, with nausea being the most common.
November 2025 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in customizing treatments and ensuring medication safety.
31 citations
,
May 2017 in “JAAD Case Reports” ATX-101 injections can cause hair loss.
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
September 2025 in “Journal of Medicinal Chemistry” AR-27 E-Chol siRNA can effectively regrow hair by reducing androgen receptor gene activity.
March 2014 in “Oxford University Press eBooks” Fludalanine failed as an effective oral antibiotic despite efforts.
January 2023 in “Brazilian Journals Editora eBooks” Pharmacists play a key role in managing the use of anxiety medications and ensuring patients use them correctly.
11 citations
,
October 2021 in “Orphanet journal of rare diseases” Patients with RASopathies are at risk for autoimmune disorders and should be routinely screened.
July 2005 in “SKINmed/Skinmed” BRL 7660, once studied for male contraception, showed promise as an acne treatment but was not developed further due to competing drugs.
6 citations
,
January 2013 in “Chemical & pharmaceutical bulletin/Chemical and pharmaceutical bulletin” A new compound shows promise as a topical treatment for hair loss.
7 citations
,
February 2019 in “Journal of pharmacological sciences” Bazhengsan reduces inflammation and tissue growth in chronic prostatitis.
The authors suggest that 5-α-reductase inhibitors, like dutasteride, are effective in treating frontal fibrosing alopecia and should be the first-line treatment, with other options for severe cases. They also recommend further research on Janus kinase inhibitors.
March 2021 in “Research Square (Research Square)” Patients with RASopathies have a higher risk of autoimmune disorders and should be routinely screened.
9 citations
,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
1 citations
,
January 2000 in “PubMed” The treatment slightly increased hair growth and was safe for most women.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.